Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other solid neoplasm 1Genitourinary 1Endocrine 1CNS 1

Conditions

Wilms Tumor 1Sarcoma, Ewing 1Rhabdomyosarcoma, Alveolar 1Rhabdomyosarcoma 1Retinoblastoma 1Neuroblastoma 1Medulloblastoma 1Glioblastoma 1Carcinoid Tumor 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × Biological Factors × Clear all
NCT00314925 2010-02-25

Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features

Neotropix

Phase 1 Unknown
60 enrolled
CNSEndocrineGenitourinaryOther solid neoplasmSarcoma

Carcinoid Tumor, Glioblastoma, Medulloblastoma, Wilms Tumor, Neuroblastoma, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Rhabdomyosarcoma, Alveolar

Data powered by HemOnc (CC BY 4.0) Colophon âš¡